Research Article

CYP19 Genetic Polymorphism Haplotype AASA Is Associated with a Poor Prognosis in Premenopausal Women with Lymph Node-Negative, Hormone Receptor-Positive Breast Cancer

Table 4

Haplotype AASA remains a significant prognostic factor for poor survival in premenopausal patients receiving adjuvant chemotherapy.

CYP19 haplotype
AASA versus non-AASA
Hazard ratio (95% CI)
aHR (95% CI)
value

OS5.1 (1.9–13.7)
6.4 (2.1–19.0)
P = 0.001
P = 0.0009

DFS2.7 (1.3–5.4)
3.2 (1.5–6.8)
P = 0.005
P = 0.003

DDFS2.9 (1.4–6.2)
4.5 (1.9–10.3)
P = 0.005
P = 0.0005